2 months Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates Zacks
Syndax (SNDX) delivered earnings and revenue surprises of 13.27% and 96.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
X